Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1411685/000165495418011619/vtgn8k_oct242018.htm
January 2023
January 2023
December 2022
December 2022
November 2022
November 2022
November 2022
November 2022
October 2022
October 2022
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1411685/000165495418011619/vtgn8k_oct242018.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Vistagen Therapeutics, Inc..
Vistagen Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Vistagen Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
Ticker: VTGNEvents:
CIK: 1411685
Form Type: 8-K Corporate News
Accession Number: 0001654954-18-011619
Submitted to the SEC: Fri Oct 26 2018 4:21:17 PM EST
Accepted by the SEC: Fri Oct 26 2018
Period: Wednesday, October 24, 2018
Industry: Pharmaceutical Preparations